Expression and clinical significance of interleukins in different subtypes of gastroesophageal reflux disease

doi:10.3877/cma.j.issn.2095-8765.2018.03.001

Abstract

Abstract:

Objective

To investigate the expression of IL-4, IL-6 in Barrett esophagus (BE), erosive esophagitis (EE) and nonerosive reflux disease (NERD) and the role they played in gastroesophageal reflux disease (GERD).

Methods

Patients of BE, EE, NERD and control group were carefully selected according to the results of GERD Questionnaire and endoscopy. 24-hour ambulatory esophageal pH monitoring was used to estimate the GERD patients' esophageal acid exposure. Esophageal biopsies taken at endoscopy in all four groups were observed in microscopy for histopathology, and tested by immunohistochemistry (IHC) staining for cytokines IL-4 and IL-6.

Results

In the 24 h pH monitoring, DeMeester score showed no significant differences in three GERD subtype groups (P>0.05), neither were the results of 4<pH<7 (weak acid) reflux event nor the total reflux event. The event of pH<4 (acid) reflux was significantly lower in NERD group (P<0.05). In the comparison of the four groups including the control of the esophageal mucosal histopathological grading, BE and EE had significantly higher inflammatory score(P<0.05); and the difference between NERD group and the control was not significant. Detecting the IL-4 expression in specimens of esophageal, there was no considerable difference between the four groups (P>0.05). The expression of IL-6 in the esophagus of NERD group and the control was significantly low or not even detected, but was markedly higher in the EE group than that in the control group (P<0.05).

Conclusions

Histological inflammation level of GERD esophageal mucosal epithelium is increased with the deterioration of esophagitis. Rather than IL-4, IL-6 is more significantly expressed in esophagus between different subtypes of GERD.

Key words: Gastroesophageal reflux disease, Nonerosive reflux disease, Barrett esophagus, Interleukin-4, Interleukin-6

Wulamu Wubulikasimu·, Aikemu Batuer·, Yisireyili Maimaiti·, Xiaoyong Liu, Abudureyimu Kelimu·. Expression and clinical significance of interleukins in different subtypes of gastroesophageal reflux disease[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2018, 05(03): 97-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2018.03.001

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2018/V05/I03/97

Figures/Tables 3

References 21

[1]	Linz D, Hohl M, Vollmar J, et al. Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction [J]. Europace, 2017, 19(1):16-20.
[2]	Martinucci I, Albano E, Marchi S, et al. Extra-esophageal presentation of gastroesophageal reflux disease: new understanding in a new era[J]. Minerva Gastroenterol Dietol, 2017, 63(3):221-234.
[3]	Sidhwa F, Moore A, Alligood E, et al. Diagnosis and Treatment of the Extraesophageal Manifestations of Gastroesophageal Reflux Disease [J]. Ann Surg, 2017, 265(1):63-67.
[4]	Dunbar KB, Agoston AT, Odze RD, et al. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes [J]. JAMA, 2016, 315(19):2104.
[5]	Okamura A, Takeuchi H, Matsuda S, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer [J]. Ann Surg Oncol, 2015, 22(9):3130-3135.
[6]	Maev IV, Lyamina SV, Capital Em CEV, et al. An immune response and an alveolar macrophage phenotype in asthma, gastroesophageal reflux disease and their concurrence [J]. Ter Arkh, 2015, 87(3):34-41.
[7]	Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD[J]. Gut, 2013, 62(6):824-832.
[8]	潘国宗，许国铭，郭慧平，等．北京上海胃食管反流症状的流行病学调查[J]．中华消化杂志, 1999, 19(4):223-226.
[9]	Nelsen E M, Kirihara Y, Takahashi N, et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus [J]. Clin Gastroenterol Hepatol, 2012, 10(7):728-734; quiz e761-722.
[10]	Ge D, You Z. Expression of interleukin-17RC protein in normal human tissues [J]. Int Arch Med, 2008, 1(1):19.
[11]	Langner C, Schneider NI, Plieschnegger W, et al. Cardiac mucosa at the gastro-oesophageal junction: indicator of gastro-oesophageal reflux disease? Data from a prospective central European multicentre study on histological and endoscopic diagnosis of oesophagitis (histoGERD trial) [J]. Histopathology, 2014, 65(1):81-89.
[12]	Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy [J]. Am J Gastroenterol, 1997, 92(8):1293-1297.
[13]	Patti MG. An Evidence-Based Approach to the Treatment of Gastroesophageal Reflux Disease [J]. JAMA Surg, 2016, 151(1):73-78.
[14]	Kandulski A, Malfertheiner P. Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation [J]. Nat Rev Gastroenterol Hepatol, 2011, 9(1):15-22.
[15]	段卓洋，张川．胃食管反流病不同亚型食管酸暴露及发病机制的差异[J].临床荟萃, 2013, 28(12):1361-1364.
[16]	Pace F, Casini V, Pallotta S. Heterogeneity of endoscopy negative heartburn: epidemiology and natural history [J]. World J Gastroenterol, 2008, 14(34):5233-5236.
[17]	肖英莲，汪安江，杨莉，等．胃食管反流病中非酸反流的比例及其与烧心的关系[J]．中华消化杂志, 2010, 30(11):793-797.
[18]	Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants [J]. Gut, 2002, 50(4):451-459.
[19]	Leoni G, Neumann PA, Sumagin R, et al. Wound repair: role of immune-epithelial interactions [J]. Mucosal Immunol, 2015, 8(5):959-968.
[20]	Semeniuk J, Wasilewska J, Kaczmarski M. Serum interleukin--4 and tumor necrosis factor alpha concentrations in children with primary acid gastroesophageal reflux and acid gastroesophageal reflux secondary to cow's milk allergy [J]. Adv Med Sci, 2012, 57(2):273-281.
[21]	Jankowski J. Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus [J]. Gut, 1993, 34(12):1649-1650.

组别	例数	pH≤4（酸反流）总次数（次）	4<pH<7（弱酸反流）总次数（次）	反流事件总次数（次）	DeMeester评分（分）
BE组	21	32.50（24.25，76.50）	14.50（6.00，41.00）	55.00（33.25，113.00）	26.95（7.21，51.60）
EE组	25	29.00（16.50，42.25）	12.00（5.75，16.00）	46.00（27.00，54.50）	31.85（21.00，48.50）
NERD组	13	17.50（9.00，31.00）^a	13.50（8.00，21.00）	39.00（20.00，49.50）	22.10（6.40，36.30）

组别	例数	pH≤4（酸反流）总次数（次）	4<pH<7（弱酸反流）总次数（次）	反流事件总次数（次）	DeMeester评分（分）
BE组	21	32.50（24.25，76.50）	14.50（6.00，41.00）	55.00（33.25，113.00）	26.95（7.21，51.60）
EE组	25	29.00（16.50，42.25）	12.00（5.75，16.00）	46.00（27.00，54.50）	31.85（21.00，48.50）
NERD组	13	17.50（9.00，31.00）^a	13.50（8.00，21.00）	39.00（20.00，49.50）	22.10（6.40，36.30）

组别	例数	IL-4		IL-6
组别	例数	阳性	阴性	阳性	阴性
对照组	10	2（20.0）	8（80.0）	0（0.0）	10（100.0）
NERD组	13	4（69.2）	9（30.8）	2（15.4）	11（84.6）
EE组	25	7（28.0）	18（72.0）	11（44.0）^a	14（56.0）
BE组	21	6（28.6）	15（71.4）	13（61.9）^a，b	8（38.1）

组别	例数	IL-4		IL-6
组别	例数	阳性	阴性	阳性	阴性
对照组	10	2（20.0）	8（80.0）	0（0.0）	10（100.0）
NERD组	13	4（69.2）	9（30.8）	2（15.4）	11（84.6）
EE组	25	7（28.0）	18（72.0）	11（44.0）^a	14（56.0）
BE组	21	6（28.6）	15（71.4）	13（61.9）^a，b	8（38.1）

Please choose a citation manager

Content to export